Smart Nanoparticles Light Up Hidden Brain Cancer During Surgery and Destroy What Remains, Showing 100% Survival in Mice

Researchers at the University of Technology Sydney, Harvard, and Henan universities have developed a 'double-punch' nanozyme platform that uses smart nanoparticles to illuminate hidden glioblastoma cells during surgery and destroy microscopic cancer left behind. In mouse models, the treatment prevented recurrence and achieved 100% survival at 60 days, compared to 42 days for surgery alone. The results were published in Science Translational Medicine.

Key Takeaways

Researchers at the University of Technology Sydney, Harvard, and Henan universities have developed a 'double-punch' nanozyme platform that uses smart nanoparticles to illuminate hidden glioblastoma cells during surgery and destroy microscopic cancer left behind.
In mouse models, the treatment prevented recurrence and achieved 100% survival at 60 days, compared to 42 days for surgery alone.
The results were published in Science Translational Medicine.

AI synthesis3 sources7

Scientists have developed a nanoparticle platform that could transform glioblastoma surgery by simultaneously illuminating hidden cancer cells and destroying what the surgeon's scalpel cannot reach.

Researchers at the University of Technology Sydney (UTS), Harvard, and Henan universities created a 'double-punch' nanozyme system that addresses two of the deadliest challenges in brain cancer treatment: the difficulty of spotting microscopic tumor clusters during surgery and the near-certainty that cancer cells left behind will cause recurrence.

The findings, published in Science Translational Medicine, describe a two-dimensional nanostructure covered with individually placed atoms — a manufacturing technique adapted from semiconductor fabrication. This material can switch between two functions activated by the same near-infrared light: first, a fluorescent dye on the surface glows to reveal individual tumor cell clusters as small as 44 micrometers, a resolution beyond current clinical imaging tools; second, after the visible tumor is removed, the same material is reactivated in the surgical cavity to perform phototherapy.

During the postoperative phase, the nanoparticles convert the tumor's own hydrogen peroxide into oxygen — counteracting the low-oxygen environment that shields cancer cells from treatment — while simultaneously generating heat and reactive molecules that destroy microscopic remnants.

"We've engineered a single material that does two jobs in sequence," said Dr. Bingyang Shi, Chair Professor of nanomedicine at UTS. "It's a precise guide for the surgeon during the operation, and then a targeted clean-up treatment afterward."

In mouse models of glioblastoma, the nanoparticle approach eliminated tumor recurrence after surgery. Every treated mouse was alive at 60 days, compared to a median survival of 42 days in the surgery-only group. Follow-up testing found no detectable neurological or motor impairments.

Glioblastoma remains the most aggressive form of brain cancer, with a five-year survival rate of roughly 7%. Cancer cells spread into surrounding brain tissue, making complete surgical removal nearly impossible without damaging healthy areas. The blood-brain barrier further limits the effectiveness of drugs and radiotherapy.

The researchers caution that results have been demonstrated only in animal models so far and that performance must be confirmed at the scale of a human brain before clinical applications can be pursued.